XML 116 R83.htm IDEA: XBRL DOCUMENT v3.22.4
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 19,102,419 13,799,117 16,220,548
Common Stock Options Granted      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 13,892,287 13,097,374 16,125,548
Nonvested Restricted Stock Units Outstanding      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 4,799,850 693,173 38,125
Nonvested Market-based Restricted Stock Units Outstanding Granted      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 410,282    
Common Stock Warrant Outstanding      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities   8,570 56,875